medRxiv PreprintsInternational19 November 2026
Kidney Function Variability and Cardiovascular Outcomes in Heart Failure: Effects of Empagliflozin in the EMPEROR-Reduced Trial
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background: Although sodium-glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular and kidney outcomes in patients with heart failure (HF), the prognostic significance of intraindividual kidney function variability and its modification by SGLT2 inhibition remain unclear. We investigated these relationships in patients with HF with reduced ejection fraction (HFrEF). Methods: This secondary analysis included 3,492 patients from the EMPEROR-Reduced trial. A location-scale joint model (LSJM) simultaneously evaluated the associations of estimated glomerular filtration rate (eGFR) levels,
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.